Co-tenidone 50/12.5mg Film-Coated Tablets

Concepts (33)

• +BreastfeedingContraindicated

  … e peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure • uncontrolled heart failure Co-tenidone tablets must not be given during pregnancy or lactation.

  Source SmPC ↗
• +Heart conditionsContraindicated

  … hould not be used in the following: • hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • sev …

  Source SmPC ↗
• +Hormone disordersContraindicated

  … • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure • uncontrolled heart failure Co-tenidone tablets must not be given during pregnancy or lactation.

  Source SmPC ↗
• +Heart rhythm blockContraindicated

  Co-tenidone should not be used in the following: • hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated pha …

  Source SmPC ↗
• +Allergy to the medicineContraindicated

  Co-tenidone should not be used in the following: • hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome …

  Source SmPC ↗
• +Low blood pressureContraindicated

  … e following: • hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure …

  Source SmPC ↗
• +Acid build-up in the bloodContraindicated

  … hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure • uncontrolled heart …

  Source SmPC ↗
• +PregnancyContraindicated

  … e peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure • uncontrolled heart failure Co-tenidone tablets must not be given during pregnancy or lactation.

  Source SmPC ↗
• +Kidney conditionsContraindicated

  … ock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure • uncontrolled heart failure Co-tenidone tablets must not be given during pregnancy or lactation.

  Source SmPC ↗
• +ShockContraindicated

  … hould not be used in the following: • hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • sev …

  Source SmPC ↗
• +UnclassifiedContraindicated

  Co-tenidone should not be used in the following: • hypersensitivity to the active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension …

  Source SmPC ↗
• +Blood vessel conditionsContraindicated

  … e active substances (or to sulphonamide derived medicinal products) or to any of the excipients listed in section 6.1 • bradycardia • cardiogenic shock • hypotension • metabolic acidosis • severe peripheral arterial circulatory disturbances • second- or third-degree heart block • sick sinus syndrome • untreated phaeochromocytoma • severe renal failure • uncontrolled heart failure Co-tenidone tablets must not be given during p …

  Source SmPC ↗
• +Angioedema (deep swelling)Warning

  … lergens, when given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline used to treat the allergic reactions. • may cause a hypersensitivity reaction including angioedema and urticaria • patients with bronchospastic disease should, in general, not receive beta blockers due to increasing in airways resistance. Atenolol is a beta1-selective beta-blocker, however this selectivity is …

  Source SmPC ↗
• +Taken with other medicinesWarning

  … mol) administered if necessary. The label and patient information leaflet for this product state the following warning: “Do not take this medicine if you have a history of wheezing or asthma.” • systemic effects of oral beta-blockers may be potentiated when used concomitantly with ophthalmic beta-blockers. • in patients with pheochromocytoma Co-tenidone must be administered only after alfa-receptor blockade. Blood pressure should be monitored closely. • caution must be exercised when using anaest …

  Source SmPC ↗
• +Salt and mineral balanceWarning

  … to uricaemia or gout since chlorthalidone may cause a rise in serum uric acid levels. Prolonged elevation can be corrected by the use of a uricosuric agent. Due to its chlortalidone component: • plasma electrolyte should be periodically determined in appropriate intervals to detect possible electrolyte imbalance especially hypokalaemia and hyponatraemia. • hypokalaemia and hyponatraemia may occur. Measurement of electrolytes is recommended, especially in the older patient, those receiving digitalis preparations for cardiac failure, those taking a …

  Source SmPC ↗
• +Stomach and gutWarning

  … s chlortalidone component: • plasma electrolyte should be periodically determined in appropriate intervals to detect possible electrolyte imbalance especially hypokalaemia and hyponatraemia. • hypokalaemia and hyponatraemia may occur. Measurement of electrolytes is recommended, especially in the older patient, those receiving digitalis preparations for cardiac failure, those taking an abnormal (low in potassium) diet or those suffering from gastrointestinal complaints. Hypokalaemia may predispose to arrhythmias in patients receiving digitalis. • impaired glucose tolerance may occur and diabetic patients should be aware of the potential for increased glucose levels. Close monitoring of glycaemia is recommended in the initial phase of ther …

  Source SmPC ↗
• +Liver conditionsWarning

  … for increased glucose levels. Close monitoring of glycaemia is recommended in the initial phase of therapy and in prolonged therapy test for glucosuria should be carries out at regular intervals. • in patients with impaired hepatic function or progressive liver disease, minor alterations in fluid and electrolyte balance may precipitate hepatic coma. • hyperuricaemia may occur. Only a minor increase in serum uric acid usually occurs but in cases of prolonged elevation, the concurrent use of a uricosuric agent will reverse the hyperuricaemia. …

  Source SmPC ↗
• +Sodium and potassium contentWarning

  … ments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. This medicine contains less than 1 mmol sodium (23mg) per tablet, that is to say essentially 'sodium-free'.

  Source SmPC ↗
• +Eye conditionsWarning

  … mol) administered if necessary. The label and patient information leaflet for this product state the following warning: “Do not take this medicine if you have a history of wheezing or asthma.” • systemic effects of oral beta-blockers may be potentiated when used concomitantly with ophthalmic beta-blockers. • in patients with pheochromocytoma Co-tenidone must be administered only after alfa-receptor blockade. Blood pressure should be monitored closely. • caution must be exercised when using anaest …

  Source SmPC ↗
• +Heart rhythm (QT interval)Warning

  … s chlortalidone component: • plasma electrolyte should be periodically determined in appropriate intervals to detect possible electrolyte imbalance especially hypokalaemia and hyponatraemia. • hypokalaemia and hyponatraemia may occur. Measurement of electrolytes is recommended, especially in the older patient, those receiving digitalis preparations for cardiac failure, those taking an abnormal (low in potassium) diet or those suffering from gastrointestinal complaints. Hypokalaemia may predispose to arrhythmias in patients receiving digitalis. • impaired glucose tolerance may occur and diabetic patients should be aware of the potential for increased glucose levels. Close monitoring of glycaemia is recommended in the initial phase of ther …

  Source SmPC ↗
• +Breathing conditionsWarning

  … d be used and utmost caution must be exercised. If increased airways resistance does occur, Co-tenidone should be discontinued and bronchodilator therapy (eg salbutamol) administered if necessary. The label and patient information leaflet for this product state the following warning: “Do not take this medicine if you have a history of wheezing or asthma.” • systemic effects of oral beta-blockers may be potentiated when used concomitantly with ophthalmic beta-blockers. • in patients with pheochromocytoma Co-tenidone must be administered only afte …

  Source SmPC ↗
• +ThyroidWarning

  … ould further increase the risk of severe hypoglycaemia when used concurrently with sulfonylureas. Diabetic patients should be advised to carefully monitor blood glucose levels. (see Section 4.5). • may mask the cardiovascular signs of thyrotoxicosis. • will reduce heart rate, as a result of its pharmacological action. In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate, the dose may be r …

  Source SmPC ↗
• +FertilityPregnancy

  Fertility: No data on fertility available. Pregnancy: Co-tenidone tablets must not be given during pregnancy. Lactation: Co-tenidone tablets must not be given during lactation.

  Source SmPC ↗
• +Alcohol—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Benzyl alcohol—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Obstructed blood flow from the heart—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Contrast dyes used in scans—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Older people—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Intolerance to an ingredient—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Blockage—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Children—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Sugar alcohols—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Propylene glycol—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.